1Y Target$35.50Near-term target
5Y Target$30.06Compound horizon
10Y Target$38.36Long-dated conviction
FCF$173mTTM · 03/26CFCF $173m — modest; watch for margin expansion · TTM computed from 4 most-recent quarters (TTM · 03/26).
Rev+10.6%TTM YoYBRevenue +10.6% — at or above S&P median
D/E0.25A-D/E 0.25 — conservative leverage, strong balance sheet
P/E3.6xAP/E 3.6 — deep value; well below S&P median (~20x)
PEG0.33APEG 0.33 — exceptional; paying well under fair value for growth
Why now
Biotechnology · market cap $1.7b. 11% off the 52-week high of $25.15. Revenue growing +11%, comfortably above the S&P median. PEG 0.33 — paying under fair value for the growth rate. 4 sell-side analysts rate this a Buy with a mean 1-yr target of $35.50 (implying +58% upside).
Moat
ROE 51% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Horizon
1-3 yr $35.50 (4-analyst consensus) — multiple re-rating thesis requires a catalyst. 5 yr $30.06 at ~6% CAGR — dividend + buyback compounding. 10 yr $38.36 if the moat survives secular pressure.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See
terms and
methodology for full disclosures.